once monthly glp 1 agonist GLP-1 Antagonists Increase Plan Drug Spend - What's Next Beyond a singular focus on

Gynecol Oncol

Persistent or severe vomiting, or inability to tolerate fluids, requires medical attention due to dehydration risk

Appeal to consumer interest The approval comes amid social media hype around GLP-1 drugs and next-generation agents like retatrutide, which influencers tout as GLP3 promising even greater weight loss

But once use moves from need to want, from clinic to culture, the ground shifts

Recently, DPP-4 inhibitors have increasingly replaced sulfonylureas as second line therapy after metformin failure and many metformin/DPP-4 inhibitor fixed dose combinations are available

Mayo Foundation for Medical Education and Research